PainReform CEO Ilan Hadar Discusses Latest Developments Related To PRF-110 To Help Tackle The Opioid Epidemic
PainReform CEO Ilan Hadar Discusses Latest Developments Related To PRF-110 To Help Tackle The Opioid Epidemic
PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, participated in an interview with Proactiveinvestors.com.
专注于成熟疗法配方的临床阶段专业制药公司PainReform Ltd.（纳斯达克股票代码：PRFX）（“PainReform” 或 “公司”）今天宣布，PainReform首席执行官伊兰·哈达尔接受了ProactiveInvestors.com的采访。
During the interview, Mr. Hadar discussed the advantages of PRF-110 to help tackle the opioid epidemic, including its ability to provide extended post-operative pain relief without the use of opioids, as well as the market potential for the product, and positive updates on the Company's ongoing Phase 3 clinical trial.
在采访中，哈达尔先生讨论了 PRF-110 在帮助应对阿片类药物流行方面的优势，包括其在不使用阿片类药物的情况下延长术后疼痛缓解的能力，以及该产品的市场潜力，以及该公司正在进行的三期临床试验的积极进展。
The interview can be viewed on Proactiveinvestors.com or on their YouTube channel:
采访可以在ProactiveInvestors.com或他们的YouTube频道上观看：